The FDA approved the first GLP-1 receptor agonist for diabetes management in 2005, and weight-management applications followed years after
He thought more products would soon enter the market and competition would drive prices down
The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet is a hybrid model that incorporates modifications based on the most compelling evidence in the diet-cognition relationships [50]
Plaintiffs allege that GLP-1 agonists drug manufacturers were aware of the link between these medications and gastroparesis based on clinical trial data yet chose not to prominently disclose or warn about this risk
The turning point came around 2015, when higher-dose liraglutide, under the brand name Saxenda, was approved for obesity, confirming the weight loss effect wasnt just a side effect, but a primary therapeutic action. GLP-1s worked differently from earlier diet drugs
Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease
